Company Description

ImmunoPrecise Antibodies Ltd. operates as an AI-driven biotherapeutic research, technology, and scientifically robust life science company.

It discovers and develops customized and novel antibodies by generating proprietary and patented processes, procedures, and innovative approaches to antibody discovery, development, and production.

The company was incorporated in 1983 and is headquartered in Austin, Texas.

ImmunoPrecise Antibodies Ltd.

Country	United States
Founded	1983
IPO Date	Jan 3, 2017
Industry	Biotechnology
Sector	Healthcare
Employees	102
CEO	Jennifer Bath

Contact Details

Address: Industrious 823 Congress Ave, Suite 300 Austin, Texas 78701 United States
Phone	800-620-4187
Website	ipatherapeutics.com

Stock Details

Ticker Symbol	IPA
Exchange	NASDAQ
Fiscal Year	May - April
Reporting Currency	CAD
CIK Code	0001715925
CUSIP Number	45257F200
ISIN Number	CA45257F2008
SIC Code	2834

Key Executives

Name	Position
Dr. Jennifer Lynne Bath Ph.D.	Chief Executive Officer, President and Non-Independent Director
Joseph Scheffler	Interim Chief Financial Officer
Dr. Ilse Roodink	Chief Scientific Officer and Interim General Manager of IPA Europe, Oss
Kari Graber	Vice President of Commercial Services
Dirk Van Hyfte M.D., Ph.D.	Chief Technology Officer
Frederic Chabot	Head of Corporate Development
Ingrid Brands M.D., Ph.D.	Chief Innovation and Strategy Officer

Latest SEC Filings

Date	Type	Title
Aug 6, 2025	6-K	Report of foreign issuer
Aug 1, 2025	6-K	Report of foreign issuer
Jul 29, 2025	6-K	Report of foreign issuer
Jul 29, 2025	20-F	Annual and transition report of foreign private issuers
Jul 24, 2025	6-K	Report of foreign issuer
Jul 21, 2025	6-K	Report of foreign issuer
Jul 14, 2025	6-K	Report of foreign issuer
Jul 7, 2025	6-K	Report of foreign issuer
Jul 3, 2025	6-K	Report of foreign issuer
Jun 24, 2025	6-K	Report of foreign issuer

View All SEC Filings